Summary by Moomoo AI
TC BioPharm, a biotechnology company, has filed its annual report for the fiscal year ended December 31, 2023. The report details the company's financial performance, business development, and future plans. Financially, TC BioPharm has not disclosed specific revenue, operating profit, net profit, or diluted earnings per share figures in the provided text. However, the company's aggregate market value of shares held by non-affiliates was approximately $3.1 million as of June 30, 2023. As of March 29, 2024, 63,902,641 ordinary shares were outstanding. The company underwent an ADS ratio change on December 15, 2023, adjusting from one ADS representing one ordinary share to one ADS representing 20 ordinary shares. In terms of business development, the company's executive team is outlined, with details on their backgrounds and experience. The...Show More